vTv Therapeutics Inc
$ 31.77
-0.90%
09 Jun - close price
- Market Cap 126,273,000 USD
- Current Price $ 31.77
- High / Low $ 32.61 / 31.40
- Stock P/E N/A
- Book Value 5.19
- EPS -0.78
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.01 %
- 52 Week High 44.00
- 52 Week Low 14.00
About
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops and sells candidates for orally administered small molecule drugs to meet unmet medical needs.
Analyst Target Price
$53.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-10 | 2025-11-06 | 2025-08-12 | 2025-05-15 | 2025-03-20 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-09 | 2023-08-11 |
| Reported EPS | 1.65 | -0.58 | -1.08 | -0.92 | -0.77 | -0.552 | -0.88 | -0.8089 | -1.1747 | -1.67 | -3.2 | -0.07 |
| Estimated EPS | 0.21 | -1.088 | -0.98 | -0.82 | -0.81 | -0.87 | -3.6 | None | None | -0.07 | -0.08 | -0.07 |
| Surprise | 1.44 | 0.508 | -0.1 | -0.1 | 0.04 | 0.318 | 2.72 | 0 | 0 | -1.6 | -3.12 | 0 |
| Surprise Percentage | 685.7143% | 46.6912% | -10.2041% | -12.1951% | 4.9383% | 36.5517% | 75.5556% | None% | None% | -2285.7143% | -3900% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTVT
2026-06-06 21:09:52
This article provides a comprehensive list of vTv Therapeutics Inc.'s (VTVT) financial disclosures and SEC filings, including Forms 10-K, 10-Q, and 8-K. It details earnings releases and quarterly/annual reports from 2020 through Q1 2026, allowing users to evaluate the company's financial performance and operational updates. The information is presented in a structured, chronological format for easy reference.
2026-06-02 15:05:00
vTv Therapeutics Inc., a late-stage biopharmaceutical company, announced it granted 2,500 stock options to a non-executive employee as an inducement to employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $34.30 per share and will vest over four years, subject to continued employment, and relate to their focus on developing cadisegliatin for type 1 diabetes.
2026-05-15 01:40:36
VTV Therapeutics (VTVT) reported a significant shift in its Q1 2026 financials, moving from quarterly losses to a profit of US$1.94 EPS and US$36.8 million in revenue. This change raises questions about the durability of the new profit profile, especially given forecasts of a 20.9% annual earnings decline over the next three years. The stock's P/S ratio of 12.9x is positioned between its peers and the wider biotech industry, prompting investors to weigh recent profitability against potential future declines and past dilution.
2026-05-14 08:40:01
vTv Therapeutics Inc. has filed a Form 8-K to announce a significant expansion of its at-the-market (ATM) equity offering program, increasing the aggregate offering price to up to $47,500,000. This move allows the company to raise substantial capital for operations, research, or clinical trials, potentially leading to dilution for existing shareholders. Investors are advised to monitor the deployment of these proceeds and consider the potential price sensitivity.
2026-05-14 00:39:27
vTv Therapeutics (NASDAQ: VTVT) reported a significant financial turnaround in Q1 2026, achieving a net income of $24.1 million, a substantial improvement from a $6.2 million loss in the prior year. This profit was primarily driven by $36.8 million in licensing revenue, including a $20.0 million upfront payment from Newsoara and recognition of deferred license consideration from G42. The company's cash and cash equivalents also increased to $98.1 million, providing greater flexibility to fund its ongoing Phase 3 clinical trials for cadisegliatin and other pipeline projects.
2026-05-13 22:40:00
vTv Therapeutics Inc. has filed with the U.S. SEC, indicating an increase in the allocation of Class A common shares under its at-the-market offering plan to the full authorized amount. This move signifies the company's intention to fully utilize its equity financing quota.
